Search Results

Purigen Biosystems, Inc. today announced a new distribution agreement with Bucher Biotec AG.

MiLaboratories, a leader in RNA immune technologies, and Miltenyi Biotec, a global pioneer in biotechnology, are excited to announce a landmark partnership that promises to revolutionize the field of next-generation therapies.

The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.

Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate - technology, announced the appointment of Ulf Grawunder, Ph.D. to its scientific advisory board.

MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.

ILiAD Biotechnologies, LLC (ILiAD) reported today that BPZE1, the most advanced next generation pertussis vaccine, demonstrated positive topline interim results in the SUPER (Stand Up to Pertussis) school-age trial conducted in 366 participants in the United Kingdom, Australia and Costa Rica.

Eternity Biotech, Inc., a biotechnology company dedicated to finding solutions for longer, healthier lives, announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.

Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease in collaboration with the Biomarkers of Aging Consortium announced the launch of the next phase of the Biomarkers of Aging Challenge Series.

Gordian Biotechnology, an in vivo drug discovery and development company, announced its platform that enables patient predictive, in vivo screening of hundreds of gene targets for FDA-recognized diseases of aging at a scale never before possible.

Sirona Biochem Corp. is pleased to announce that its innovative anti-aging ingredient, GlycoProteMim™, has been featured in Stonegate Healthcare’s newly published research report, “Novel Treatments for Age-Related Skin Problems.” The report provides an in-depth analysis of the latest advancements in the $12.5 billion anti-aging skincare market.